hCG

Human chorionic gonadotropin

Grade A: Approved and proven

TL;DR: hCG (human chorionic gonadotropin) is an FDA-approved prescription drug with well-established indications, and this distinguishes it categorically from research peptides. It is approved for treating hypogonadotropic hypogonadism in males, stimulating spermatogenesis, treating cryptorchidism in prepubertal boys, and inducing ovulation in women. Controlled trial evidence supports its use for fertility outcomes in men with hypogonadotropic hypogonadism, where it stimulates testicular testosterone and sperm production. One small RCT found hCG and clomiphene citrate comparably effective at restoring testosterone in hypogonadism. Evidence for late-onset or age-related hypogonadism (i.e., low-T not caused by a pituitary deficiency) is weaker, consisting largely of observational series; results are mixed, and the labeled indication is hypogonadotropic hypogonadism specifically, not primary hypogonadism. Klinefelter syndrome studies show limited benefit. The evidence base is real but narrower than often claimed in wellness contexts.

Key Takeaways

Grade A: Approved and proven
FDA approved: FDA-approved prescription biologic for hypogonadotropic hypogonadism, cryptorchidism, and ovulation induction; compounding prohibited due to biologic classification.
Compounding: hCG is an FDA-approved biologic (Pregnyl, Novarel, and others). However, as a biologic, it is prohibited from 503A compounding pharmacy preparation as of recent FDA guidance; it must be obtained as the licensed pharmaceutical product through a prescription. Use outside its labeled indications (e.g., weight loss protocols) is not FDA-approved.

Mechanism

Mimics luteinizing hormone (LH) at LH/hCG receptors in the testes, stimulating Leydig cell testosterone production and supporting Sertoli cell function for spermatogenesis.

Evidence

hCG (human chorionic gonadotropin) is an FDA-approved prescription drug with well-established indications, and this distinguishes it categorically from research peptides. It is approved for treating hypogonadotropic hypogonadism in males, stimulating spermatogenesis, treating cryptorchidism in prepubertal boys, and inducing ovulation in women. Controlled trial evidence supports its use for fertility outcomes in men with hypogonadotropic hypogonadism, where it stimulates testicular testosterone and sperm production. One small RCT found hCG and clomiphene citrate comparably effective at restoring testosterone in hypogonadism. Evidence for late-onset or age-related hypogonadism (i.e., low-T not caused by a pituitary deficiency) is weaker, consisting largely of observational series; results are mixed, and the labeled indication is hypogonadotropic hypogonadism specifically, not primary hypogonadism. Klinefelter syndrome studies show limited benefit. The evidence base is real but narrower than often claimed in wellness contexts.

Safety and risks

FDA labeling includes warnings about potential for ovarian hyperstimulation syndrome in women and premature puberty in boys if used inappropriately. A theoretical concern that prolonged LH-receptor stimulation could promote growth in androgen-sensitive or gonadotropin-sensitive tumors is noted in the literature; magnitude of risk in clinical use is not firmly quantified. hCG is classified as a biologic (it is a glycoprotein hormone); FDA has restricted its compounding, making it effectively unavailable through 503A compounding pharmacies. Off-label use for weight loss is not supported by evidence and has been the subject of FDA warnings. Use in men with testosterone above normal range lacks evidence of benefit and the safety implications of further elevation are not well characterized. Exogenous hCG suppresses endogenous LH signal and its long-term effects on the hypothalamic-pituitary-gonadal axis with extended use are incompletely characterized.

Interactions

May interact with testosterone replacement therapy (concurrent use can preserve testicular function but the combined hormonal effect requires monitoring). Use alongside aromatase inhibitors or other HPG-axis-active agents requires physician oversight.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

hCG is an FDA-approved biologic (Pregnyl, Novarel, and others). However, as a biologic, it is prohibited from 503A compounding pharmacy preparation as of recent FDA guidance; it must be obtained as the licensed pharmaceutical product through a prescription. Use outside its labeled indications (e.g., weight loss protocols) is not FDA-approved.

Sources

hCG is FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).